// App-Quantinova.ai

196 : The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).

Researchers

Presenter

  • Lauren Christine Harshman

Principal Investigators

  • Lillian Werner

  • Mari Nakabayashi

  • Abhishek Tripathi

  • Rana R. McKay

  • Xiaodong Wang

  • Mark Pomerantz

  • Lorelei A. Mucci

  • Mary-Ellen Taplin

  • Christopher Sweeney

  • Gwo-Shu Mary Lee

  • Philip W. Kantoff

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Harvard School of Public Health, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved